Press Releases April 22, 2026 04:05 PM

LifeVantage to Announce Third Quarter Fiscal Year 2026 Results on May 6, 2026

LifeVantage sets May 6, 2026 date to announce Q3 fiscal 2026 financial results with conference call and webcast.

By Ajmal Hussain LFVN
LifeVantage to Announce Third Quarter Fiscal Year 2026 Results on May 6, 2026
LFVN

LifeVantage Corporation announced it will release its financial results for the third quarter ended March 31, 2026, after market close on May 6, 2026. The company will host a conference call and live webcast for investors to discuss the quarter's performance. LifeVantage is a health and wellness company specializing in nutrigenomics-based products.

Key Points

  • LifeVantage to report Q3 fiscal 2026 results on May 6, 2026 after market close.
  • The company will hold an investor conference call and webcast the same day.
  • LifeVantage offers nutrigenomics-driven health products through independent consultants.
  • Sectors impacted include health and wellness, nutraceuticals, and direct selling markets.

SALT LAKE CITY, April 22, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2026, after the stock market closes on Wednesday, May 6, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, May 20, 2026, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13759699, or (412) 317-6671 from international locations, and entering confirmation code 13759699.

There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations or directly at https://viavid.webcasts.com/starthere.jsp?ei=1758157&tp_key=76e0807216. The webcast will be archived for approximately 30 days.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and the comprehensive gut activator, P84, and activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

Investor Relations Contact:

Reed Anderson, ICR
(646) 277-1260
[email protected]


Risks

  • Financial results may not meet market expectations, affecting stock price.
  • Dependence on independent consultants for product sales could impact revenue stability.
  • Market competition in health and wellness may affect growth prospects.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026